These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 36823338)

  • 1. TIMEAS, a promising method for the stratification of testicular germ cell tumor patients with distinct immune microenvironment, clinical outcome and sensitivity to frontline therapies.
    Meng J; Gao J; Li X; Gao R; Lu X; Zhou J; Yan F; Wang H; Liu Y; Hao Z; Zhang X; Liang C
    Cell Oncol (Dordr); 2023 Jun; 46(3):745-759. PubMed ID: 36823338
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic value of programmed-death-1 receptor (PD-1) and its ligand 1 (PD-L1) in testicular germ cell tumors.
    Cierna Z; Mego M; Miskovska V; Machalekova K; Chovanec M; Svetlovska D; Hainova K; Rejlekova K; Macak D; Spanik S; Ondrus D; Kajo K; Mardiak J; Babal P
    Ann Oncol; 2016 Feb; 27(2):300-5. PubMed ID: 26598537
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genomic stratification based on microenvironment immune types and PD-L1 for tailoring therapeutic strategies in bladder cancer.
    Lyu X; Wang P; Qiao Q; Jiang Y
    BMC Cancer; 2021 May; 21(1):646. PubMed ID: 34059019
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of new biomarkers in immune microenvironment of testicular germ cell tumour.
    Song Y; Qi X; Kang J; Wang X; Ou N; Zhu J; Wang S; Liu X
    Andrologia; 2021 Apr; 53(3):e13986. PubMed ID: 33544925
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor immune microenvironment-based classifications of bladder cancer for enhancing the response rate of immunotherapy.
    Meng J; Lu X; Zhou Y; Zhang M; Ge Q; Zhou J; Hao Z; Gao S; Yan F; Liang C
    Mol Ther Oncolytics; 2021 Mar; 20():410-421. PubMed ID: 33665361
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic role of programmed-death ligand 1 (PD-L1) expressing tumor infiltrating lymphocytes in testicular germ cell tumors.
    Chovanec M; Cierna Z; Miskovska V; Machalekova K; Svetlovska D; Kalavska K; Rejlekova K; Spanik S; Kajo K; Babal P; Mardiak J; Mego M
    Oncotarget; 2017 Mar; 8(13):21794-21805. PubMed ID: 28423520
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical Response of a Patient to Anti-PD-1 Immunotherapy and the Immune Landscape of Testicular Germ Cell Tumors.
    Shah S; Ward JE; Bao R; Hall CR; Brockstein BE; Luke JJ
    Cancer Immunol Res; 2016 Nov; 4(11):903-909. PubMed ID: 27638840
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular heterogeneity of anti-PD-1/PD-L1 immunotherapy efficacy is correlated with tumor immune microenvironment in East Asian patients with non-small cell lung cancer.
    Jin R; Liu C; Zheng S; Wang X; Feng X; Li H; Sun N; He J
    Cancer Biol Med; 2020 Aug; 17(3):768-781. PubMed ID: 32944405
    [No Abstract]   [Full Text] [Related]  

  • 9. Identification and validation of novel microenvironment-based immune molecular subgroups of head and neck squamous cell carcinoma: implications for immunotherapy.
    Chen YP; Wang YQ; Lv JW; Li YQ; Chua MLK; Le QT; Lee N; Colevas AD; Seiwert T; Hayes DN; Riaz N; Vermorken JB; O'Sullivan B; He QM; Yang XJ; Tang LL; Mao YP; Sun Y; Liu N; Ma J
    Ann Oncol; 2019 Jan; 30(1):68-75. PubMed ID: 30407504
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long Non-Coding RNA RFPL3S Functions as a Biomarker of Prognostic and Immunotherapeutic Prediction in Testicular Germ Cell Tumor.
    Guo J; Wang S; Jiang Z; Tang L; Liu Z; Cao J; Hu Z; Chen X; Luo Y; Bo H
    Front Immunol; 2022; 13():859730. PubMed ID: 35669771
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differences in PD-L1-Expressing Macrophages and Immune Microenvironment in Testicular Germ Cell Tumors.
    Sadigh S; Farahani SJ; Shah A; Vaughn D; Lal P
    Am J Clin Pathol; 2020 Feb; 153(3):387-395. PubMed ID: 31802108
    [TBL] [Abstract][Full Text] [Related]  

  • 12. T cells in testicular germ cell tumors: new evidence of fundamental contributions by rare subsets.
    Islam R; Heyer J; Figura M; Wang X; Nie X; Nathaniel B; Indumathy S; Hartmann K; Pleuger C; Fijak M; Kliesch S; Dittmar F; Pilatz A; Wagenlehner F; Hedger M; Loveland B; Hotaling JH; Guo J; Loveland KL; Schuppe HC; Fietz D
    Br J Cancer; 2024 Jun; 130(12):1893-1903. PubMed ID: 38649788
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genomic Characterization of Testicular Germ Cell Tumors Relapsing After Chemotherapy.
    Necchi A; Bratslavsky G; Corona RJ; Chung JH; Millis SZ; Elvin JA; Vergilio JA; Suh J; Ramkissoon S; Severson E; Daniel S; Killian JK; Ali SM; Schrock AB; Reddy P; Miller VA; Welsh A; Gay LM; Ross JS
    Eur Urol Focus; 2020 Jan; 6(1):122-130. PubMed ID: 30025711
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mitochondrial metabolism-related signature depicts immunophenotype and predicts therapeutic response in testicular germ cell tumors.
    Qiu D; Gao L; Zhang S; Lin G; Yu X
    Medicine (Baltimore); 2023 Sep; 102(37):e35120. PubMed ID: 37713839
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cancer Stem Cell Niche and Immune-Active Tumor Microenvironment in Testicular Germ Cell Tumors.
    Kalavska K; Kucerova L; Schmidtova S; Chovanec M; Mego M
    Adv Exp Med Biol; 2020; 1226():111-121. PubMed ID: 32030680
    [TBL] [Abstract][Full Text] [Related]  

  • 16. βcatenin is a marker of poor clinical characteristics and suppressed immune infiltration in testicular germ cell tumors.
    Chovanec M; Cierna Z; Miskovska V; Machalekova K; Kalavska K; Rejlekova K; Svetlovska D; Macak D; Spanik S; Kajo K; Babal P; Mego M; Mardiak J
    BMC Cancer; 2018 Nov; 18(1):1062. PubMed ID: 30390643
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Toll-like receptor 2 (TLR2) is a candidate prognostic factor in testicular germ cell tumors as well as an indicator of immune function in the tumor microenvironment.
    Wu H; Zhang Z; Xiao XY; Zhang ZY; Gao SL; Lu C; Zuo L; Zhang LF
    Bioengineered; 2021 Dec; 12(1):1939-1951. PubMed ID: 34002664
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of programmed death ligand-1 (PD-L1) in metastatic and postchemotherapy viable testicular germ cell tumors.
    Al-Hogbani M; Duguay J; Wagner DC; Haferkamp A; Joubert P; Frees S; Rendon R; Power N; Périgny M; Toren P
    Urol Oncol; 2021 May; 39(5):303.e1-303.e8. PubMed ID: 33685799
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Wilms tumor gene 1 (WT1), TP53, RAS/BRAF and KIT aberrations in testicular germ cell tumors.
    Boublikova L; Bakardjieva-Mihaylova V; Skvarova Kramarzova K; Kuzilkova D; Dobiasova A; Fiser K; Stuchly J; Kotrova M; Buchler T; Dusek P; Grega M; Rosova B; Vernerova Z; Klezl P; Pesl M; Zachoval R; Krolupper M; Kubecova M; Stahalova V; Abrahamova J; Babjuk M; Kodet R; Trka J
    Cancer Lett; 2016 Jul; 376(2):367-76. PubMed ID: 27085458
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regulatory T-cells-related signature for identifying a prognostic subtype of hepatocellular carcinoma with an exhausted tumor microenvironment.
    Zhang G
    Front Immunol; 2022; 13():975762. PubMed ID: 36189226
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.